Instrument Inactif

Autres langues Kuros Biosciences AG Swiss Exchange

Actions

CH0325814116

Temps réel estimé Cboe Europe Autres places de cotation 12:01:14 29/04/2024			Varia. 5j.	Varia. 1 janv.
6,585 ^CHF	+174,38 %		+0,42 %	+3,91 %

24/04	Bourse Zurich: retour dans le rouge, Roche plombe l'indice	AW
24/04	Les ventes de Kuros s'envolent	AW

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Kuros mit erneut starkem Umsatz- und Ergebnissprung im ersten Quartal	24/04
Kuros Biosciences Posts Higher Q1 Product Sales	24/04
Kuros reports Corporate Highlights as of Q1 2024 including increase in direct MagnetOsTM sales	24/04
Kuros Biosciences AG Approves Board of Director and Committee Changes	17/04
Annual General Meeting of Kuros Biosciences approves all resolutions	17/04
Kuros Biosciences' FY23 Attributable Loss Shrinks; Revenue Up	13/03
Kuros hat nach Umsatzsprung den Verlust verringert	13/03
Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023	13/03
Kuros Biosciences AG Reports Earnings Results for the Full Year Ended December 31, 2023	12/03
Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update	08/03
Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference	01/02
US FDA Approves Kuros Biosciences' Bone Graft Granules for Interbody Use	31/01
Kuros erhält weitere Zulassung für MagnetOs in den USA und Neuseeland	31/01
Kuros Biosciences Receives US FDA 510K Clearance for Magnetos Granules for Interbody Use and Regulatory Clearance of Magnetos Granules and Magnetos Putty in New Zealand	31/01
Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand	31/01
Kuros stellt neue Daten vor und erhält zwei weitere FDA-Zulassungen	04/01
Kuros Biosciences Announces Three Advancements Related to its MagnetOs Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA	04/01
Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA	04/01
Aktien Schweiz nach Weihnachtspause etwas leichter	27/12
Kuros konzentriert sich auf MagnetOs - Fibrin-PTH kommt nicht in Phase III	27/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Kuros Biosciences AG Swiss Exchange

Actions

CH0325814116

Autres langues

Filtres